UTHR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

818.74M

+11.26%

6.878

+11.12%

817.94M

+2.96%

7.017

+5.83%

847.01M

+6.06%

7.207

+12.43%

Estimates Revision

The market is revising Downward the revenue expectations for United Therapeutics Corporation (UTHR) for FY2025, with the revenue forecasts being adjusted by -0.09% over the past three months. During the same period, the stock price has changed by 22.40%.

Revenue Estimates for FY2025

Revise Downward

-0.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.97%

In Past 3 Month

Stock Price

Go Up

+22.40%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 520.00 USD with a low forecast of 423.00 USD and a high forecast of 600.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

4 Hold

0 Sell

Moderate Buy

Current: 492.480

Low

423.00

Averages

520.00

High

600.00

Current: 492.480

Low

423.00

Averages

520.00

High

600.00

UBS

Buy

maintain

$580 -> $600

2025-11-06

Reason

UBS

Price Target

$580 -> $600

2025-11-06

maintain

Buy

Reason

UBS raised the firm's price target on United Therapeutics to $600 from $580 and keeps a Buy rating on the shares.

Morgan Stanley

Equal Weight

maintain

$435 -> $447

2025-10-30

Reason

Morgan Stanley

Price Target

$435 -> $447

2025-10-30

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on United Therapeutics to $447 from $435 and keeps an Equal Weight rating on the shares. Despite a Q3 miss, shares traded up following commentary on the call regarding the potential for a Tyvaso rest-of-the-world partnerships following recent Phase 3 IPF data, the analyst noted. During the post Q3 follow up call, management noted that the commentary was meant to suggest that the company is open to partnerships and collaborations, but that there are no active discussions, the analyst tells investors.

RBC Capital

Lisa Walter

Outperform

maintain

$569 -> $587

2025-10-30

Reason

RBC Capital

Lisa Walter

Price Target

$569 -> $587

2025-10-30

maintain

Outperform

Reason

RBC Capital analyst Lisa Walter raised the firm's price target on United Therapeutics to $587 from $569 and keeps an Outperform rating on the shares. The company's Q3 results support the firm's view that Tyvaso will continue to grow irrespective of new market entrants, IPF could double the top-line to over $6B in the next 5 years, and the base business will show resiliency, the analyst tells investors in a research note.

H.C. Wainwright

Andrew Fein

Buy

maintain

$500 -> $525

2025-10-30

Reason

H.C. Wainwright

Andrew Fein

Price Target

$500 -> $525

2025-10-30

maintain

Buy

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on United Therapeutics to $525 from $500 and keeps a Buy rating on the shares following the Q3 report. The firm cites Tyvaso revenue growth and the "strong" early launch of Yutrepia for the target boost.

Jefferies

Roger Song

Buy

maintain

$564 -> $575

2025-10-29

Reason

Jefferies

Roger Song

Price Target

$564 -> $575

2025-10-29

maintain

Buy

Reason

Jefferies analyst Roger Song raised the firm's price target on United Therapeutics to $575 from $564 and keeps a Buy rating on the shares. The firm notes the company put out another revenue record quarter, with Tyvaso as key driver. Also, the company is open to various partnerships such as ex-U.S. for Tyvaso and relinepag with potential to combo with other MOA including Winrevair. Overall, Jefferies believes the set-up is even stronger following the quarter.

UBS

Buy

maintain

$560 -> $580

2025-09-29

Reason

UBS

Price Target

$560 -> $580

2025-09-29

maintain

Buy

Reason

UBS raised the firm's price target on United Therapeutics to $580 from $560 and keeps a Buy rating on the shares. The Tyvaso IPF data from the TETON-2 study could drive a positive stock reaction as the best-in-class efficacy and safety was re-confirmed, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for United Therapeutics Corp (UTHR.O) is 17.38, compared to its 5-year average forward P/E of 12.34. For a more detailed relative valuation and DCF analysis to assess United Therapeutics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.34

Current PE

17.38

Overvalued PE

14.24

Undervalued PE

10.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

6.65

Current EV/EBITDA

10.20

Overvalued EV/EBITDA

8.10

Undervalued EV/EBITDA

5.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.78

Current PS

6.34

Overvalued PS

5.37

Undervalued PS

4.19

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

UTHR News & Events

Events Timeline

No data

News

4.5

12-05NASDAQ.COM

Significant Withdrawals Observed in ETF for SPMD, COHR, LITE, UTHR

6.5

12-01Barron's

Younger Investors Continue to Favor Sustainable Investing: Insights from an Expert's Selections.

8.0

11-25NASDAQ.COM

Significant Options Activity on Tuesday: UTHR, GOOGL, META

People Also Watch

Frequently Asked Questions

What is United Therapeutics Corp (UTHR) stock price today?

The current price of UTHR is 492.48 USD — it has decreased -0.31 % in the last trading day.

What is United Therapeutics Corp (UTHR)'s business?

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

What is the price predicton of UTHR Stock?

What is United Therapeutics Corp (UTHR)'s revenue for the last quarter?

United Therapeutics Corp revenue for the last quarter amounts to 799.50M USD, increased 6.76 % YoY.

What is United Therapeutics Corp (UTHR)'s earnings per share (EPS) for the last quarter?

United Therapeutics Corp. EPS for the last quarter amounts to 7.16 USD, increased 12.05 % YoY.

What changes have occurred in the market's expectations for United Therapeutics Corp (UTHR)'s fundamentals?

How many employees does United Therapeutics Corp (UTHR). have?

United Therapeutics Corp (UTHR) has 1305 emplpoyees as of December 15 2025.

What is United Therapeutics Corp (UTHR) market cap?

Today UTHR has the market capitalization of 21.27B USD.